Structural basis of topoisomerase targeting by delafloxacin.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40595483.
- Also identified by DOI 10.1038/s41467-025-60688-3 and PMC identifier 12217528.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Delafloxacin is a potent anionic fluoroquinolone approved for the treatment of respiratory infections that acts by trapping the DNA cleavage complexes of bacterial topoisomerase IV and gyrase. Its N-1-pyridinyl-, C-7-azetidinyl- and C-8-chlorine substituents confer enhanced antibiotic activity against bacteria resistant to other fluoroquinolones, but its mode of action is unclear. Here we present the X-ray crystal structures of a delafloxacin-DNA cleavage complex obtained by co-crystallization with Streptococcus pneumoniae topo IV using a graphene nucleant and solved at 2.0 and 2.4 Å resolution. The two Mg<sup>2+</sup>-chelated delafloxacin molecules intercalated at the DNA cleavage site are bound in an unusual conformation involving interacting out-of-plane N-1-aromatic- and C-8-chlorine- substituents. The unprecedented resolution allows comprehensive imaging of water-metal ion links integrating enzyme and DNA through drug-bound and active-site Mg<sup>2+</sup> ions plus the discovery of enzyme-bound K<sup>+</sup> ions. Our studies on delafloxacin action suggest that intrinsic target affinity contributes to its activity against quinolone-resistant bacteria.
Medical subject headings
- Fluoroquinolones
- DNA Topoisomerase IV
- Streptococcus pneumoniae
- Anti-Bacterial Agents